At a roundtable discussion from the 2014 American Society of Clinical Oncology (ASCO) meeting, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center and Dr. Olatoyosi Odenike from University of Chicago Medical Center joined Dr. Srdan Verstovsek from MD Anderson Cancer Center to review the latest advancement in the treatment of MPNs. The experts examine how the development of ruxolitinib (Jakafi®) has influenced enrollment in clinical trials. They also review the promises of combination therapy and how DNA tests will affect treatment moving forward.
Get email alerts | http://www.patientpower.inf...
2014 ASCO Coverage: Advancing MPN Treatment Through Clinical Trials – http://flip.it/68r4J